About: The war against the SARS-CoV2 infection: Is it better to fight or mitigate it?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The war against the SARS-CoV2 infection: Is it better to fight or mitigate it? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The war against the SARS-CoV2 infection: Is it better to fight or mitigate it?
Creator	Moro, Vendramin, Igor Dal Moro, Fabrizio Livi, Ugolino Fabrizio, Dal
Source	Elsevier; Medline; PMC
abstract	In trying to understand the biochemical mechanism involved in the recent pandemic COVID-19, there is currently growing interest in angiotensin-converting enzyme II (ACE2). Nevertheless, the attempts to counteract COVID-19 interference with this enzymatic cascade are frustrating, and the results have thus far been inconclusive. Let's start again by considering the involved factors in an alternative way: we could postulate that COVID-19 could be more aggressive/fatal due to a high level of “basal” inflammation with low Nitric Oxide (NO) levels in hypertensive, diabetic and obese patients. Interestingly, the “protective” effects of several factors (such as estrogens) may play a role by increasing the formation of endogenous NO. From a therapeutic point of view, phosphodiesterase type 5 inhibitors such as oral Tadalafil, could be used in order to increase the basal NO levels. In this way, we don't fight the virus, but we may be able to mitigate its effects.
has issue date	2020-07-22(xsd:dateTime)
bibo:doi	10.1016/j.mehy.2020.110129
bibo:pmid	32721814
has license	no-cc
sha1sum (hex)	3ca59ccbdead7c04dabce8a5b361f6611361beef
schema:url	https://doi.org/10.1016/j.mehy.2020.110129
resource representing a document's title	The war against the SARS-CoV2 infection: Is it better to fight or mitigate it?
has PubMed Central identifier	PMC7373683
has PubMed identifier	32721814
schema:publication	Med Hypotheses
resource representing a document's body	covid:3ca59ccbdead7c04dabce8a5b361f6611361beef#body_text
is schema:about of	named entity 'FAR' named entity 'Nevertheless' named entity 'Nitric Oxide' named entity 'hypertensive' named entity 'C-reactive protein' named entity 'Sildenafil Citrate' named entity 'pulmonary hypertension' named entity 'fulminant' named entity 'animal tests' named entity 'SARS-CoV2' named entity 'evolution' named entity 'coronavirus' named entity 'cytokine storm' named entity 'ACE2' named entity 'angiotensin-converting enzyme' named entity 'diabetes mellitus' named entity 'PDE5' named entity 'lung injury' named entity 'PDE5' named entity 'ACE2' named entity 'ClinicalTrials.gov' named entity 'IL-6' named entity 'Nitric Oxide' named entity 'pathogenesis' named entity 'Nitric Oxide' named entity 'viral infection' named entity 'ACE2' named entity 'COVID-19' named entity 'ACE2' named entity 'angiotensin-converting enzyme' named entity 'SARS-CoV2' named entity 'COVID' named entity 'Nitric Oxide' named entity 'pathological condition' named entity 'cytokine storm' named entity 'CD4 +' named entity 'IL-6' named entity 'infection' named entity 'Coronavirus' named entity 'inflammation' named entity 'COVID' named entity 'monocytes' named entity 'high levels' named entity 'ACE2' named entity 'initial phase' named entity 'ARDS' named entity 'COVID' named entity 'hypertensive' named entity 'SARS-CoV2' named entity 'Nitric Oxide' named entity 'chronic obstructive pulmonary disease' named entity 'diabetic' named entity 'cardiac failure' named entity 'mechanical ventilation' named entity 'infection' named entity 'prognosis' named entity 'Nitric Oxide' named entity 'Hypertension' named entity 'infection' named entity 'intravenous' named entity 'angiotensin-converting enzyme' named entity 'cytokine' named entity 'vascular endothelium' named entity 'Acute Respiratory Distress Syndrome' named entity 'animal studies' named entity 'Nitric Oxide' named entity 'Tadalafil' named entity 'infectious disease' named entity 'asymptomatic' named entity 'Nitric Oxide' named entity 'Nitric Oxide' named entity 'COVID' named entity 'ACE2' named entity 'endothelium' named entity 'PDE5' named entity 'infection' named entity 'Tadalafil'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software